Hematology & Oncology Doctors in Greensboro, NC Accepting Medicare

6 Hematology & Oncology doctors found. Showing 1 - 6

Yan Feng, Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

Dr. Peter Robert Ennever, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

Dr. John Thomas Dorsey Iv, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

Dr. Naga Venkata Kalipraveena Iruku, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

Ni Gorsuch, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

Dr. Vinay Kumar Gudena, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100

News Archive

Colonoscopy preparation drugs administered same day as procedure equally effective: Researchers

Researchers at Thomas Jefferson University have found that colonoscopy preparation drugs administered the same day as the procedure are equally effective to those given the night before and the morning of the procedure, but result in less complaints of side effects such as abdominal pain, sleep loss and workday interference.

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

Ranbaxy receives approval to manufacture and market Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

Read more Medical News

› Verified 9 days ago